{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:40:37Z","timestamp":1780461637520,"version":"3.54.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009148","name":"Queen Mary University of London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009148","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370444"],"award-info":[{"award-number":["82370444"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070464"],"award-info":[{"award-number":["82070464"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.drudis.2023.103788","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T12:59:18Z","timestamp":1695387558000},"page":"103788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential"],"prefix":"10.1016","volume":"28","author":[{"given":"Jingjing","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suowen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2023.103788_b0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries","volume":"134","author":"Mills","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2023.103788_b0010","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Risk Factors Collaborators","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2023.103788_b0015","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 international society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2023.103788_b0020","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2023.103788_b0025","doi-asserted-by":"crossref","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","article-title":"Hypertension","volume":"4","author":"Oparil","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.drudis.2023.103788_b0030","series-title":"Hypertension: A companion to Braunwald\u2019s heart disease","first-page":"33","article-title":"Pathogenesis of hypertension","author":"Hall","year":"2018"},{"key":"10.1016\/j.drudis.2023.103788_b0035","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/jama.2022.19590","article-title":"Treatment of hypertension: a review","volume":"328","author":"Carey","year":"2022","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.drudis.2023.103788_b0040","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.07.026","article-title":"Antihypertensive drugs","volume":"124","author":"Laurent","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2023.103788_b0045","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cell.2022.12.014","article-title":"From ABCD to E for endothelin in resistant hypertension","volume":"186","author":"Abraham","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2023.103788_b0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1573402115666191011111402","article-title":"Nantes university hospital working group on hypertension. Resistant hypertension: novel insights","volume":"16","author":"Lamirault","year":"2020","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.drudis.2023.103788_b0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrneph.2012.260","article-title":"Resistant hypertension\u2013its identification and epidemiology","volume":"9","author":"Sarafidis","year":"2013","journal-title":"Nature Rev Nephrol"},{"key":"10.1016\/j.drudis.2023.103788_b0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.drudis.2023.103788_b0065","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2023.103788_b9000","author":"New Potential Treatments for Resistant Hypertension","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.drudis.2023.103788_b0070","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2023.103788_b0075","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/pathophysiology28040031","article-title":"Circulating levels of endothelin-1 and big endothelin-1 in patients with essential hypertension","volume":"28","author":"Kostov","year":"2021","journal-title":"Pathophysiology"},{"key":"10.1016\/j.drudis.2023.103788_b0080","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/pr.115.011833","article-title":"Endothelin","volume":"68","author":"Davenport","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.drudis.2023.103788_b0085","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0140-6736(94)92827-4","article-title":"Contribution of endogenous generation of endothelin-1 to basal vascular tone","volume":"344","author":"Haynes","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2023.103788_b0090","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.bjp.0702315","article-title":"Secretory pathways in endothelin synthesis","volume":"126","author":"Russell","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2023.103788_b0095","series-title":"Physiology, Endothelin","author":"Titus","year":"2023"},{"key":"10.1016\/j.drudis.2023.103788_b0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1096\/fj.10-161612","article-title":"Endothelin-1 gene regulation","volume":"25","author":"Stow","year":"2011","journal-title":"FASEB J"},{"key":"10.1016\/j.drudis.2023.103788_b0105","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1161\/ATVBAHA.109.193540","article-title":"Flow activation of AMP-activated protein kinase in vascular endothelium leads to Kruppel-like factor 2 expression","volume":"29","author":"Young","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.drudis.2023.103788_b0110","first-page":"11","article-title":"Oxidized LDL regulates endothelin-1 and oxidative stress in vascular endothelial cells: role of extracellular regulated kinase1\/2 (ERK1\/2)","volume":"2","author":"Xu","year":"2023","journal-title":"Int J Drug Discovery Pharmacol"},{"key":"10.1016\/j.drudis.2023.103788_b0115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.lfs.2013.12.199","article-title":"miRNA-1 regulates endothelin-1 in diabetes","volume":"98","author":"Feng","year":"2014","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2023.103788_b0120","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.febslet.2012.02.044","article-title":"The inhibitory effect of miRNA-1 on ET-1 gene expression","volume":"586","author":"Li","year":"2012","journal-title":"FEBS Lett"},{"key":"10.1016\/j.drudis.2023.103788_b0125","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1097\/HJH.0b013e32833a4922","article-title":"MicroRNA-125a\/b-5p inhibits endothelin-1 expression in vascular endothelial cells","volume":"28","author":"Li","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.drudis.2023.103788_b0130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3892\/or.2014.3598","article-title":"Emerging role of microRNAs in modulating endothelin-1 expression in gastric cancer","volume":"33","author":"Tsai","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.drudis.2023.103788_b0135","article-title":"The lncRNA MALAT1 participates in regulating coronary slow flow endothelial dysfunction through the miR-181b-5p-MEF2A-ET\u20131 axis","volume":"138","author":"Zhao","year":"2021","journal-title":"VascPharmacol"},{"key":"10.1016\/j.drudis.2023.103788_b0140","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cell.2017.06.049","article-title":"A genetic variant associated with five vascular diseases is a distal regulator of endothelin-1 gene expression","volume":"170","author":"Gupta","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2023.103788_b0145","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1093\/eurheartj\/ehz915","article-title":"Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction","volume":"41","author":"Ford","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.drudis.2023.103788_b0150","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/j.1476-5381.1995.tb13322.x","article-title":"Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type","volume":"114","author":"Davenport","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2023.103788_b0155","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1158\/0008-5472.CAN-16-3229","article-title":"Endothelin promotes colorectal tumorigenesis by activating YAP\/TAZ","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2023.103788_b0160","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1124\/pharmrev.120.000096","article-title":"Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies","volume":"73","author":"Xu","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.drudis.2023.103788_b0165","doi-asserted-by":"crossref","first-page":"23098","DOI":"10.1074\/jbc.M311430200","article-title":"Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK\/ERK","volume":"279","author":"Xu","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2023.103788_b0170","doi-asserted-by":"crossref","first-page":"e0161988","DOI":"10.1371\/journal.pone.0161988","article-title":"Stimulation of transforming growth factor-beta1-induced endothelial-to-mesenchymal transition and tissue fibrosis by endothelin-1 (ET-1): a novel profibrotic effect of ET-1","volume":"11","author":"Wermuth","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2023.103788_b0175","doi-asserted-by":"crossref","first-page":"9129960","DOI":"10.1155\/2022\/9129960","article-title":"Association of endothelin-converting enzyme and endothelin-1 gene polymorphisms with essential hypertension in Malay ethnics","volume":"2022","author":"Salim","year":"2022","journal-title":"Genet Res (Camb)"},{"key":"10.1016\/j.drudis.2023.103788_b0180","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1164\/rccm.201501-0196OC","article-title":"Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension","volume":"192","author":"Benza","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.drudis.2023.103788_b0185","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00380-014-0544-1","article-title":"Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension","volume":"30","author":"Hatano","year":"2015","journal-title":"Heart Vessels"},{"key":"10.1016\/j.drudis.2023.103788_b0190","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/1346-8138.13497","article-title":"Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: prospective, multicenter, open-label study","volume":"44","author":"Hamaguchi","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.drudis.2023.103788_b0195","doi-asserted-by":"crossref","first-page":"e003896","DOI":"10.1161\/JAHA.116.003896","article-title":"Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials","volume":"5","author":"Wei","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.drudis.2023.103788_b0200","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/jcpt.13481","article-title":"Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: a meta-analysis","volume":"47","author":"Zhao","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.drudis.2023.103788_b0205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1527-3466.2006.00063.x","article-title":"Ambrisentan, a non-peptide endothelin receptor antagonist","volume":"24","author":"Vatter","year":"2006","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.drudis.2023.103788_b0210","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1016\/j.bmcl.2016.06.014","article-title":"From bosentan (Tracleer\u00ae) to macitentan (Opsumit\u00ae): the medicinal chemistry perspective","volume":"26","author":"Boss","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2023.103788_b0215","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1517\/14740338.2014.859674","article-title":"Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension","volume":"13","author":"Dingemanse","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.drudis.2023.103788_b0220","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/jpet.118.253864","article-title":"Pharmacological characterization of aprocitentan, a dual endothelin receptor antagonist, alone and in combination with blockers of the renin angiotensin system, in two models of experimental hypertension","volume":"368","author":"Trensz","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2023.103788_b0225","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1517\/13543784.11.7.991","article-title":"Bosentan: a dual endothelin receptor antagonist","volume":"11","author":"Rubin","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.drudis.2023.103788_b0230","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","article-title":"Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist","volume":"327","author":"Iglarz","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2023.103788_b0235","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2147\/DDDT.S199051","article-title":"Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects","volume":"13","author":"Sidharta","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.drudis.2023.103788_b0240","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s40261-019-00837-x","article-title":"Single-dose pharmacokinetics and tolerability of aprocitentan, a dual endothelin receptor antagonist, in subjects with severe renal function impairment","volume":"39","author":"Sidharta","year":"2019","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.drudis.2023.103788_b0245","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/cpdd.881","article-title":"Multiple-dose pharmacokinetics, safety, and tolerability of aprocitentan, a dual endothelin receptor antagonist, in healthy Japanese and Caucasian subjects","volume":"10","author":"Fontes","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.drudis.2023.103788_b0250","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2174\/1389200222666210204202815","article-title":"Absorption, distribution, metabolism, and excretion of aprocitentan, a dual endothelin receptor antagonist, in humans","volume":"22","author":"Sidharta","year":"2021","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.drudis.2023.103788_b0255","doi-asserted-by":"crossref","first-page":"19067","DOI":"10.1038\/s41598-022-22470-z","article-title":"Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment","volume":"12","author":"Fontes","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2023.103788_b0260","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/HYPERTENSIONAHA.119.14504","article-title":"Randomized dose-response study of the new dual endothelin receptor antagonist aprocitentan in hypertension","volume":"75","author":"Verweij","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2023.103788_b9005","unstructured":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022 Dec 3; 400(10367): 1927\u20131937."},{"key":"10.1016\/j.drudis.2023.103788_b0265","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2023.103788_b0270","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cpdd.815","article-title":"Effects of multiple-dose administration of aprocitentan on the pharmacokinetics of rosuvastatin","volume":"9","author":"Sidharta","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.drudis.2023.103788_b0275","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s13318-019-00590-8","article-title":"Effect of multiple-dose aprocitentan administration on the pharmacokinetics of midazolam in healthy male subjects","volume":"45","author":"Sidharta","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.drudis.2023.103788_b0280","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/cpt.2043","article-title":"Effects of the dual endothelin receptor antagonist aprocitentan on body weight and fluid homeostasis in healthy subjects on a high sodium diet","volume":"109","author":"Gueneau de Mussy","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2023.103788_b0285","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The transition from hypertension to heart failure: contemporary update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.drudis.2023.103788_b0290","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"29","author":"Visseren","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.drudis.2023.103788_b0295","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1185\/030079904X4185","article-title":"Provision of cardiovascular protection by ACE inhibitors: a review of recent trials","volume":"20","author":"Bertrand","year":"2004","journal-title":"Curr Med Res Opin"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623003045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623003045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:03:34Z","timestamp":1778601814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644623003045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1359644623003045"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103788","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103788"}}